Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist

被引:179
作者
Park, SH [1 ]
Saleh, D [1 ]
Giaid, A [1 ]
Michel, RP [1 ]
机构
[1] MCGILL UNIV,DEPT PATHOL,MONTREAL,PQ H3A 2B4,CANADA
关键词
D O I
10.1164/ajrccm.156.2.9607123
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is characterized by an alveolitis with epithelial and endothelial damage progressing to fibrosis. Numerous mediators have been implicated in this complex process. Studies in humans have shown that endothelin-l (ET-1), a vasoconstrictor and mitogenic peptide, is a mediator in IPF. To determine the role of ET-1 and endothelin-converting enzyme (ECE)-1 and the effect of bosentan, an ET receptor antagonist, in an animal model of IPF, we studied three groups of rats (n = 6 each): Group 1, control, received saline; Group 2, fibrosis, received 1.5 U bleomycin intratracheally; Group 3, fibrosis-bosentan treated, received bleomycin and bosentan daily by gavage. After 28 d, right upper lobes were fixed for immunohistochemistry (IHC) and sections were stained with antisera to ET-1 and ECE-1 and graded semiquantitatively. Sections from left lungs were embedded in paraffin and stained for light microscopic morphometry to quantitate the fibrosis. By IHC, we found increased ET-1 immunoreactivity (ir) in airway epithelium and inflammatory cells, and ECE-l-ir in airway epithelium, type II pneumocytes and endothelial cells (p < 0.05). By morphometry, the volume fraction (Vv) of connective tissue (CT) increased and the Vv of air decreased in the fibrosis group compared with that in the control group. Bosentan reduced the Vv of CT and increased the Vv of air compared with that in the fibrosis group (p < 0.05). These results indicate that ET-1 is involved in the pathogenesis of pulmonary fibrosis in the rodent model and that blockage of its receptors reduces the fibrosis.
引用
收藏
页码:600 / 608
页数:9
相关论文
共 37 条
  • [1] ADAMSON IYR, 1974, AM J PATHOL, V77, P185
  • [2] CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR
    ARAI, H
    HORI, S
    ARAMORI, I
    OHKUBO, H
    NAKANISHI, S
    [J]. NATURE, 1990, 348 (6303) : 730 - 732
  • [3] ENDOTHELINS AND PULMONARY-DISEASES
    BARNES, PJ
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1994, 77 (03) : 1051 - 1059
  • [4] Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates
    Bartholomeusz, B
    Hardy, KJ
    Nelson, AS
    Phillips, PA
    [J]. HYPERTENSION, 1996, 27 (06) : 1341 - 1345
  • [5] GROWTH REGULATORY PROPERTIES OF ENDOTHELINS
    BATTISTINI, B
    CHAILLER, P
    DORLEANSJUSTE, P
    BRIERE, N
    SIROIS, P
    [J]. PEPTIDES, 1993, 14 (02) : 385 - 399
  • [6] Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
    Chen, SJ
    Chen, YF
    Meng, QC
    Durand, J
    Dicarlo, VS
    Oparil, S
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1995, 79 (06) : 2122 - 2131
  • [7] CURRENT CONCEPTS IN IDIOPATHIC PULMONARY FIBROSIS - A ROAD MAP FOR THE FUTURE
    CHERNIACK, RM
    CRYSTAL, RG
    KALICA, AR
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (03): : 680 - 683
  • [8] CLOZEL M, 1994, J PHARMACOL EXP THER, V270, P228
  • [9] INTERSTITIAL LUNG-DISEASES OF UNKNOWN CAUSE .1. DISORDERS CHARACTERIZED BY CHRONIC INFLAMMATION OF THE LOWER RESPIRATORY-TRACT
    CRYSTAL, RG
    BITTERMAN, PB
    RENNARD, SI
    HANCE, AJ
    KEOGH, BA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (03) : 154 - 166
  • [10] PROTECTION FROM PULMONARY-HYPERTENSION WITH AN ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST IN HYPOXIC RATS
    EDDAHIBI, S
    RAFFESTIN, B
    CLOZEL, M
    LEVAME, M
    ADNOT, S
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (02): : H828 - H835